Clinical Trials Logo

Filter by:
NCT ID: NCT00808067 Completed - Atrial Fibrillation Clinical Trials

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Start date: November 2008
Phase: Phase 3
Study type: Interventional

The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes

NCT ID: NCT00805194 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Start date: December 3, 2008
Phase: Phase 3
Study type: Interventional

The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.

NCT ID: NCT00805168 Completed - Clinical trials for Pneumonia, Bacterial

Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

INHALE 2
Start date: May 28, 2013
Phase: Phase 3
Study type: Interventional

To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on ventilation, and the days in the intensive care unit (ICU).

NCT ID: NCT00803049 Completed - Multiple Sclerosis Clinical Trials

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) patients with relapse. The secondary objective is to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.

NCT ID: NCT00801957 Completed - Atopic Dermatitis Clinical Trials

Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis

Start date: March 2003
Phase: Phase 2
Study type: Interventional

Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.

NCT ID: NCT00801944 Completed - Clinical trials for Urinary Bladder, Overactive

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms

SUNRISE
Start date: April 2004
Phase: Phase 3
Study type: Interventional

Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.

NCT ID: NCT00801541 Completed - Clinical trials for Age-related Macular Degeneration

Characterization of Early Markers of Choroidal Neovascularization

CNV-Markers
Start date: December 2005
Phase: N/A
Study type: Observational

To this study and identify the sequence of alterations occurring in the chorioretinal interface during progression of AMD from "dry" AMD to sight-threatening chorioretinal neovascularization (CNV).

NCT ID: NCT00798434 Completed - Clinical trials for Urinary Bladder, Overactive

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

SOFIA
Start date: June 2008
Phase: Phase 4
Study type: Interventional

The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged > 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment.

NCT ID: NCT00797641 Completed - Clinical trials for Gastrointestinal Hemorrhage

European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)

ENERGIB
Start date: January 2009
Phase: N/A
Study type: Observational

The aim of this study is to assess the current management strategies in a pan-European "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.

NCT ID: NCT00797524 Completed - Clinical trials for Diabetic Retinopathy

Function and Structure Imaging in Different Retinal Diseases: Retinal Leakage Analyzer Versus Optical Coherence Tomography

Start date: November 2008
Phase: N/A
Study type: Observational

The main objective of this observational study is to characterize and correlate functional and structural changes at the retinal level using the Retinal Leakage Analyzer (RLA) and the Optical Coherence Tomograph (OCT). To show if it is possible to use OCT as an indirect measurement of leakage, this study will check, in a primary analysis, for OCT changes between fluorescein leaking and non-leaking areas (identified by Retinal Leakage Analyzer). As a secondary objective, changes in RLA and OCT over time (between two consecutive visits) will be analyzed and characterized. The results of this study will be used exclusively for scientific purposes.